BNC KOREA, Inc. (KOSDAQ:256840)
South Korea · Delayed Price · Currency is KRW 2,660.00
+40.00 (1.53%)
Sep 4, 2026, 3:30 PM KST
BNC KOREA Revenue
BNC KOREA had revenue of 24.61B KRW in the quarter ending June 30, 2026, a decrease of -0.10%. This brings the company's revenue in the last twelve months to 91.19B, down -8.21% year-over-year. In the year 2025, BNC KOREA had annual revenue of 95.90B with 7.47% growth.
Revenue (ttm)
91.19B
Revenue Growth
-8.21%
P/S Ratio
2.00
Revenue / Employee
345.40M
Employees
264
Market Cap
181.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 95.90B | 6.67B | 7.47% |
| Dec 31, 2024 | 89.23B | 8.23B | 10.16% |
| Dec 31, 2023 | 81.00B | 38.69B | 91.47% |
| Dec 31, 2022 | 42.30B | 17.05B | 67.55% |
| Dec 31, 2021 | 25.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Daewon Pharmaceutical | 614.64B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Whan In Pharm | 273.47B |
| JW Lifescience | 253.71B |
| Daihan Pharmaceutical | 216.55B |
| Yungjin Pharm. | 158.79B |
| REYON Pharmaceutical | 143.37B |